Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications

J. C. Moon, B. Godman, M. Petzold, S. Alvarez-Madrazo, K. Bennett, I. Bishop, A. Bucsics, U. Hesse, A. Martin, S. Simoens, C. Zara, R. E. Malmström

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Introduction: There is an urgent need for health authorities across Europe to fully realise potential savings from increased use of generics to sustain their healthcare systems. A variety of strategies were used across Europe following the availability of generic losartan, the first angiotensin receptor blocker [ARB] to be approved and marketed, to enhance its prescribing versus single-sourced drugs in the class. Demand-side strategies ranged from 100% copayment for patented ARBs in Denmark to no specific measures. We hypothesised this heterogeneity of approaches would provide opportunities to explore prescribing in a class following patent expiry. Objective: Contrast the impact of the different approaches among European countries and regions to the availability of generic losartan to provide future guidance. Methodology: Retrospective segmented regression analyses applying linear random coefficient models with country specific intercepts and slopes were used to assess the impact of the various initiatives across Europe following the availability of generic losartan. Utilisation measured in defined daily doses (DDDs). Price reductions for generic losartan were also measured. Results: Utilisation of losartan was over 90% of all ARBs in Denmarkby the study end. Multiple measures in Sweden and one English primary care group also appreciably enhanced losartan utilisation. Losartan utilisation actually fell in some countries with no specific demand-side measures. Considerable differences were seen in the prices of generic losartan. Conclusion: Delisting single-sourced ARBs produced the greatest increase in losartan utilisation. Overall, multiple demand-side measures are needed to change physician prescribing habits to fully realise savings from generics. There is no apparent 'spill over' effect from one class to another to influence future prescribing patterns even if these are closely related.

LanguageEnglish
Article number219
Number of pages10
JournalFrontiers in Pharmacology
Volume5
DOIs
Publication statusPublished - 8 Oct 2014

Fingerprint

Losartan
Angiotensin Receptor Antagonists
Denmark
Sweden
Habits
Primary Health Care
Regression Analysis
Delivery of Health Care
Physicians
Health

Keywords

  • cross-national study
  • demand-side measures
  • Europe
  • generics
  • losartan

Cite this

Moon, J. C. ; Godman, B. ; Petzold, M. ; Alvarez-Madrazo, S. ; Bennett, K. ; Bishop, I. ; Bucsics, A. ; Hesse, U. ; Martin, A. ; Simoens, S. ; Zara, C. ; Malmström, R. E. / Different initiatives across Europe to enhance losartan utilisation post generics : impact and implications. In: Frontiers in Pharmacology . 2014 ; Vol. 5.
@article{db2cab9c651e414bb0ab6f643b06f818,
title = "Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications",
abstract = "Introduction: There is an urgent need for health authorities across Europe to fully realise potential savings from increased use of generics to sustain their healthcare systems. A variety of strategies were used across Europe following the availability of generic losartan, the first angiotensin receptor blocker [ARB] to be approved and marketed, to enhance its prescribing versus single-sourced drugs in the class. Demand-side strategies ranged from 100{\%} copayment for patented ARBs in Denmark to no specific measures. We hypothesised this heterogeneity of approaches would provide opportunities to explore prescribing in a class following patent expiry. Objective: Contrast the impact of the different approaches among European countries and regions to the availability of generic losartan to provide future guidance. Methodology: Retrospective segmented regression analyses applying linear random coefficient models with country specific intercepts and slopes were used to assess the impact of the various initiatives across Europe following the availability of generic losartan. Utilisation measured in defined daily doses (DDDs). Price reductions for generic losartan were also measured. Results: Utilisation of losartan was over 90{\%} of all ARBs in Denmarkby the study end. Multiple measures in Sweden and one English primary care group also appreciably enhanced losartan utilisation. Losartan utilisation actually fell in some countries with no specific demand-side measures. Considerable differences were seen in the prices of generic losartan. Conclusion: Delisting single-sourced ARBs produced the greatest increase in losartan utilisation. Overall, multiple demand-side measures are needed to change physician prescribing habits to fully realise savings from generics. There is no apparent 'spill over' effect from one class to another to influence future prescribing patterns even if these are closely related.",
keywords = "cross-national study, demand-side measures , Europe, generics , losartan",
author = "Moon, {J. C.} and B. Godman and M. Petzold and S. Alvarez-Madrazo and K. Bennett and I. Bishop and A. Bucsics and U. Hesse and A. Martin and S. Simoens and C. Zara and Malmstr{\"o}m, {R. E.}",
year = "2014",
month = "10",
day = "8",
doi = "10.3389/fphar.2014.00219",
language = "English",
volume = "5",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",

}

Moon, JC, Godman, B, Petzold, M, Alvarez-Madrazo, S, Bennett, K, Bishop, I, Bucsics, A, Hesse, U, Martin, A, Simoens, S, Zara, C & Malmström, RE 2014, 'Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications' Frontiers in Pharmacology , vol. 5, 219. https://doi.org/10.3389/fphar.2014.00219

Different initiatives across Europe to enhance losartan utilisation post generics : impact and implications. / Moon, J. C.; Godman, B.; Petzold, M.; Alvarez-Madrazo, S.; Bennett, K.; Bishop, I.; Bucsics, A.; Hesse, U.; Martin, A.; Simoens, S.; Zara, C.; Malmström, R. E.

In: Frontiers in Pharmacology , Vol. 5, 219, 08.10.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Different initiatives across Europe to enhance losartan utilisation post generics

T2 - Frontiers in Pharmacology

AU - Moon, J. C.

AU - Godman, B.

AU - Petzold, M.

AU - Alvarez-Madrazo, S.

AU - Bennett, K.

AU - Bishop, I.

AU - Bucsics, A.

AU - Hesse, U.

AU - Martin, A.

AU - Simoens, S.

AU - Zara, C.

AU - Malmström, R. E.

PY - 2014/10/8

Y1 - 2014/10/8

N2 - Introduction: There is an urgent need for health authorities across Europe to fully realise potential savings from increased use of generics to sustain their healthcare systems. A variety of strategies were used across Europe following the availability of generic losartan, the first angiotensin receptor blocker [ARB] to be approved and marketed, to enhance its prescribing versus single-sourced drugs in the class. Demand-side strategies ranged from 100% copayment for patented ARBs in Denmark to no specific measures. We hypothesised this heterogeneity of approaches would provide opportunities to explore prescribing in a class following patent expiry. Objective: Contrast the impact of the different approaches among European countries and regions to the availability of generic losartan to provide future guidance. Methodology: Retrospective segmented regression analyses applying linear random coefficient models with country specific intercepts and slopes were used to assess the impact of the various initiatives across Europe following the availability of generic losartan. Utilisation measured in defined daily doses (DDDs). Price reductions for generic losartan were also measured. Results: Utilisation of losartan was over 90% of all ARBs in Denmarkby the study end. Multiple measures in Sweden and one English primary care group also appreciably enhanced losartan utilisation. Losartan utilisation actually fell in some countries with no specific demand-side measures. Considerable differences were seen in the prices of generic losartan. Conclusion: Delisting single-sourced ARBs produced the greatest increase in losartan utilisation. Overall, multiple demand-side measures are needed to change physician prescribing habits to fully realise savings from generics. There is no apparent 'spill over' effect from one class to another to influence future prescribing patterns even if these are closely related.

AB - Introduction: There is an urgent need for health authorities across Europe to fully realise potential savings from increased use of generics to sustain their healthcare systems. A variety of strategies were used across Europe following the availability of generic losartan, the first angiotensin receptor blocker [ARB] to be approved and marketed, to enhance its prescribing versus single-sourced drugs in the class. Demand-side strategies ranged from 100% copayment for patented ARBs in Denmark to no specific measures. We hypothesised this heterogeneity of approaches would provide opportunities to explore prescribing in a class following patent expiry. Objective: Contrast the impact of the different approaches among European countries and regions to the availability of generic losartan to provide future guidance. Methodology: Retrospective segmented regression analyses applying linear random coefficient models with country specific intercepts and slopes were used to assess the impact of the various initiatives across Europe following the availability of generic losartan. Utilisation measured in defined daily doses (DDDs). Price reductions for generic losartan were also measured. Results: Utilisation of losartan was over 90% of all ARBs in Denmarkby the study end. Multiple measures in Sweden and one English primary care group also appreciably enhanced losartan utilisation. Losartan utilisation actually fell in some countries with no specific demand-side measures. Considerable differences were seen in the prices of generic losartan. Conclusion: Delisting single-sourced ARBs produced the greatest increase in losartan utilisation. Overall, multiple demand-side measures are needed to change physician prescribing habits to fully realise savings from generics. There is no apparent 'spill over' effect from one class to another to influence future prescribing patterns even if these are closely related.

KW - cross-national study

KW - demand-side measures

KW - Europe

KW - generics

KW - losartan

UR - http://www.scopus.com/inward/record.url?scp=84907924559&partnerID=8YFLogxK

U2 - 10.3389/fphar.2014.00219

DO - 10.3389/fphar.2014.00219

M3 - Article

VL - 5

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 219

ER -